# Cilostazol

```text
DRUG INFORMATION

  ADULT
    - If symptoms are unimproved after 3 months, discontinue cilostazol tablets. 2.2
      Dose Reduction with CYP3A4 and CYP2C19 Inhibitors Reduce dose to 50 mg twice daily
      when coadministered with strong or moderate inhibitors of CYP3A4 (e.g.,
      ketoconazole, itraconazole, erythromycin, and diltiazem) or inhibitors of CYP2C19
      (e.g., ticlopidine, fluconazole, and omeprazole) [ see Drug Interactions ( 7.1 )]
      Source: US FDA label for cilostazol (Cilostazol), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Safety and effectiveness of cilostazol in pediatric patients have not been
      established.
      Source: US FDA label for cilostazol (Cilostazol), section 'pediatric use',
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Patients with moderate or severe hepatic impairment have not been studied in
      clinical trials and dosing recommendations cannot be provided [see Clinical
      Pharmacology ( 12.3 )]. 8.7 Renal Impairment No dose adjustment is required in
      patients with renal impairment .
      Source: US FDA label for cilostazol (Cilostazol), section 'use in specific
      populations', retrieved 2026-08-29
    - Patients on dialysis have not been studied, but, it is unlikely that cilostazol
      can be removed efficiently by dialysis because of its high protein binding (95 to
      98%) [see Clinical Pharmacology ( 12.3 )].
      Source: US FDA label for cilostazol (Cilostazol), section 'use in specific
      populations', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Pharmacokinetic studies have not disclosed any age-related effects on the
      absorption, distribution, metabolism, and elimination of cilostazol and its
      metabolites. 8.6 Hepatic Impairment No dose adjustment is required in patients
      with mild hepatic impairment.
      Source: US FDA label for cilostazol (Cilostazol), section 'use in specific
      populations', retrieved 2026-08-29
    - Patients with moderate or severe hepatic impairment have not been studied in
      clinical trials and dosing recommendations cannot be provided [see Clinical
      Pharmacology ( 12.3 )]. 8.7 Renal Impairment No dose adjustment is required in
      patients with renal impairment .
      Source: US FDA label for cilostazol (Cilostazol), section 'use in specific
      populations', retrieved 2026-08-29

  PREGNANCY
    - Teratogenic Effects Pregnancy Category C .
      Source: US FDA label for cilostazol (Cilostazol), section 'pregnancy', retrieved
      2026-08-29
    - Cilostazol has been shown to be teratogenic in rats at doses that are greater than
      5-times the human MRHD on a body surface area basis.
      Source: US FDA label for cilostazol (Cilostazol), section 'pregnancy', retrieved
      2026-08-29
    - There are no adequate and well-controlled studies in pregnant women.
      Source: US FDA label for cilostazol (Cilostazol), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Transfer of cilostazol into milk has been reported in rats.
      Source: US FDA label for cilostazol (Cilostazol), section 'nursing mothers',
      retrieved 2026-08-29
    - Because many drugs are excreted in human milk and because of the potential for
      serious adverse reactions in nursing infants from cilostazol, discontinue nursing
      or discontinue cilostazol.
      Source: US FDA label for cilostazol (Cilostazol), section 'nursing mothers',
      retrieved 2026-08-29
    - When cilostazol was administered to rats during late pregnancy and lactation, an
      increased incidence of stillborn and decreased birth weights of offspring was seen
      at doses of 150 mg/kg/day (5 times the MRHD on a systemic exposure basis). 8.3
      Nursing Mothers Transfer of cilostazol into milk has been reported in rats.
      Source: US FDA label for cilostazol (Cilostazol), section 'use in specific
      populations', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)